Summary
Objective: To determine the types, prevalence and development of respiratory abnormalities in patients with systemic sclerosis (SSc), and to correlate the results with clinical and serological findings. Methods: 176 patients with SSc observed longitudinally were retrospectively included in the study. The change per year of vital capacity (VC), forced expiratory volume in one second/vital capacity (FEV1/VC), diffusing capacity (DLco) and diffusing constant (Kco) of carbon monoxide from the first till the latest pulmonary function test were correlated to clinical and serological findings, including anti-centromere, anti-Scl-70, and antinucleolar antibodies. Results: An isolated reduction of DLco was seen in 47% and a restrictive ventilatory pattern in 25% of the patients. Restrictive ventilatory pattern correlated to pulmonary fibrosis, dyspnoea, a low prevalence (13%) of anti-centromere antibodies and a high prevalence of anti-Scl-70 antibodies (36%). Progression of DLco reduction was related to long disease duration, presence of anti-centromere antibodies and absence of treatment with penicillamine. Conclusion: Pulmonary involvement is common in patients with SSc. The occurrence of different serological abnormalities in patients with restrictive disease and in patients with progressive isolated reduction of DLco, suggests that the two types of pulmonary damage may have different pathogeneses rather than being different stages in the progression of pulmonary damage.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Steen VD, Owens GR, Fino GJ, Rodnan GP, Medsger TA. Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum 1985; 28: 759–67.
Guttadauria M, Ellman H, Emmanuel G, Kaplan D, Diamond H. Pulmonary function in scleroderma. Arthritis Rheum 1977; 20: 10719.
Steen VD, Graham G, Conte C, Owens G, Medsger TA. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992; 35: 765–70.
Langevitz P, Buskila D. Scleroderma hypertensive renal crisis and the changing pattern of mortality in systemic sclerosis (scleroderma). Nephron 1991; 57: 111–2.
Schneider PD, Wise RA, Hochberg MC, Wigley FM. Serial pulmonary function in systemic sclerosis. Am J Med 1982; 73: 385–94.
Abramson MJ, Barnett AJ, Littlejohn GO, Smith MM, Hall S. Lung function abnormalities and decline of spirometry in scleroderma: an overrated danger? Postgrad Med J 1991; 67: 632–7.
Greenwald GI, Tashkin DP, Gong H, Simmons M, Duann S, Furst DE, Clements P. Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis. Am J Med 1987; 83: 83–92.
Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA. Pulmonary hypertension in the CREST variant of systemic sclerosis. Arthritis Rheum 1986; 29: 515–24.
Steen VD, Owens GR, Redmond C, Rodnan GP, Medsger TA. The effect of D-penicillamine on pulmonary findings in systemic sclerosis. Arthritis Rheum 1985; 282: 882–8.
Åkesson A, Blom-Bülow B, Scheja A, Wollmer P, Valind S, Wollheim FA. Long-term evaluation of penicillamine or cyclofenil in systemic sclerosis. Scand J Rheumatol 1992; 21: 238–44.
Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581–90.
Masi AT. Classification of systemic sclerosis (scleroderma): Relationship of cutaneous subgroups in early disease to outcome and serologic reactivity. J Rheumatol 1988; 15: 894–8.
Quanjer PH. Standardized lung function testing. Report of working party on standardization of lung function tests of the European Community for Coal and Steel. Bull Physiopath Resp 1983; 19 (suppl 5).
Humbel RL. Detection of antinuclear antibodies by immunofluorescence. In: van Venroij, W.J., Maini, R.N. editors. Manual of biological markers of disease — A2. Kluwer Academic Publishers, Dordrecht, 1993: 1–16.
Steen VD, Powell DL, Medsger TA. Clinical correlations and prognosis based on serum antibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 31: 196–203.
Steen VD, Conte C, Owens GR, Medsger TA. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37: 1283–9.
Owens GR, Fino GJ, Herbert DL, Steen VD, Medsger TA, Pennock BE, Cottrell JJ, Rodnan GP, Rogers RM. Pulmonary function in progressive systemic sclerosis: comparison of CREST syndrome variant with diffuse scleroderma. Chest 1983; 84: 546–50.
Silver RM, Miller KS, Kinsella MB, Smith EA, Schabel SI. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990; 88: 470–6.
De Clerck LS, Dequeker J, Francx L, Demedts M. D-penicillamine therapy and interstitial lung disease in scleroderma. Arthritis Rheum 1987; 30: 643–50.
Martinez Cordero E. Antinuclear antibodies associated with pulmonary involvement in systemic sclerosis. Chest 1989; 96: 9601.
Young RH, Mark GJ. Pulmonary vascular changes in scleroderma. Am J Med 1978; 64: 998–1004.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jacobsen, S., Halberg, P., Ullman, S. et al. A longitudinal study of pulmonary function in Danish patients with systemic sclerosis. Clin Rheumatol 16, 384–390 (1997). https://doi.org/10.1007/BF02242456
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02242456